AlphAIAlphAI — Financial news for AI agents
tradingview.comSEP 32 min read$JNJ

J&J Gains as AbbVie Posts 74% Myeloma Response

J&J shares rose 1% to $277.955. AbbVie's experimental myeloma drug showed 74% response rate, 60% risk reduction. J&J's Carvykti drove 6.8% operational growth in Q2. Reuters notes AbbVie's drug complements, not replaces, J&J's treatment. J&J's stock is 44.08% above GF Value estimate.

Original reporting
tradingview.com
Published Sep 3, 2026, 9:26 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Sep 4, 2026, 4:27 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
J&J Gains as AbbVie Posts 74% Myeloma Response — source image
Source · tradingview.com
Decision brief

The 30-second read

$JNJBullishMed
01

Why it matters

Both companies face competitive dynamics in multiple myeloma; AbbVie's data is a fresh catalyst, while JNJ's stock movement reflects investor sentiment.

02

Market read

The trial data could reshape market expectations for myeloma treatments and influence biotech valuations.

03

What to watch

Potential regulatory hurdles and the need for confirmatory Phase 3 data could temper enthusiasm.

Relevance 8/10Novelty 8/10Timing: today

Background

The article compares AbbVie's new myeloma data to Johnson & Johnson's Carvykti franchise, noting market reactions.

Company-level read

Ticker impact

$JNJBullishHigh confidence
Context

Johnson & Johnson stock rose ~1% after AbbVie announced strong myeloma trial results, prompting market reaction.

Expected impact

modest upside for JNJ in the near term

Evidence & confidence

The trial data highlights a competitor's breakthrough but analysts see JNJ's Carvykti pipeline as still strong.

$ABBVBullishHigh confidence
Context

AbbVie reported a 74% response rate for its experimental myeloma drug etentamig, a fresh clinical trial disclosure.

Expected impact

significant upside as investors price in potential market expansion

Evidence & confidence

Phase data with 74% response and 60% risk reduction is material and novel, suggesting commercial potential.

Market effects

Sector

Boosts outlook for the broader oncology/biotech sector as trial success may spur investor interest.

Regional

U.S. biotech stocks could see modest gains following the announcement.

Global

International competitors may reassess pipelines, but primary impact is on U.S. listed biotech.

Counterpoint

What could challenge this read

Some investors may view AbbVie's data as a short‑term hype, questioning long‑term differentiation versus CAR‑T therapies.

Key entities

  • Company
    Johnson & Johnson

    U.S. healthcare conglomerate with CAR‑T product Carvykti.

  • Company
    AbbVie

    Pharmaceutical firm reporting new myeloma trial results.

Read at source← All news

Related articles

OCT 5
$ABBVMed

AbbVie Announced Its 340B Rebate Pilot on October 2. Here’s What It Means for the Stock Before Vraylar’s 2027 Medicare Price Cut

AbbVie (ABBV) announced a 340B Rebate Model Pilot for Vraylar, Linzess, and Imbruvica, effective October 2. The company faces Medicare price cuts for these drugs in 2027. Q2 2026 immunology revenue rose 15.1%. AbbVie's CEO criticized the 340B program and highlighted global pricing disputes. The stock has a mid-target price of $362, implying a ~38% total return.

tikr.com3 min
OCT 3
$MRKHigh

Big Pharma Bets $2.2 Billion on Previously 'Undruggable' KRAS G12D; Race for Pancreatic Cancer Targeted Therapies Heats Up

Merck and Bayer have invested billions in KRAS G12D inhibitors for pancreatic cancer, with Merck paying $2.13B for a preclinical candidate. Johnson & Johnson and Eli Lilly are also developing therapies, while Revolution Medicines' RMC-6236 received FDA approval. Competition is intense, with first-to-market advantages and high commercial potential.

finance.biggo.com3 min
OCT 3
$ABBVMed

AbbVie, Amgen, Pfizer, GSK among participants in new 340B rebate pilot

The Trump administration selected 10 drugmakers, including AbbVie, Amgen, Pfizer, and GSK, for a 340B rebate pilot program starting January 1. The program tests a rebate model for 21 discounted drugs under the 340B program. The HRSA oversees the initiative, aiming to address compliance proactively. The program is contentious, with pharmaceutical companies and hospitals disputing its impact.

tradingview.com2 min
OCT 2
$EWHighAI 8/10

Weekly Buzz: EW, ABBV, MIRM Score FDA Wins, AZN, NVO Strike Deals; LLY, KOD Report Data

Edwards Lifesciences (EW) received FDA approval for a pediatric heart valve. Ceribell (CBLL) and SI-BONE (SIBN) cleared new software and spinal fusion systems. Teva (TEVA) added a biosimilar to its portfolio. AbbVie (ABBV) and Mirum (MIRM) gained FDA approvals for Parkinson's and rare disease treatments. Merck (MRK) withdrew a lung cancer drug filing. Sanofi (SNY) and Regeneron (REGN) expanded their immunology alliance.

rttnews.com3 min
OCT 2
$JNJMed

Johnson & Johnson Announces New ICOTYDE Icotrokinra Data In Difficult-To-Treat Plaque Psoriasis With Proven Durability Through 2 Years

Johnson & Johnson reported two-year data from the ICONIC-TOTAL study, showing sustained skin clearance in patients with high-impact plaque psoriasis treated with ICOTYDE. At Week 112, 70% of patients achieved clear or almost clear skin, with high rates of site-specific clearance. Safety findings were consistent with ICOTYDE's established profile. The drug is approved in the U.S., Europe, Japan, and China for plaque psoriasis and is being studied for other conditions.

marketscreener.com2 min